Key result
Recent advances in heart failure management, including angiotensin receptor-neprilysin inhibitors, SGLT2 inhibitors, and left ventricular assist devices, offer new therapeutic options.
Why the study?
Despite improvements in hospitalization and survival, 5-year mortality in heart failure remains high and disease prevalence is rising.
This review highlights the expanding therapeutic armamentarium for heart failure, including novel pharmacological agents and advanced device therapies that improve patient outcomes.
Answers are grounded in this paper and cite their sources.
These advances may expand options for eligible HF patients; extends prior syntheses but leaves optimal integration open for trials.
Hospitalization rates and survival of patients with Heart Failure (HF) have improved. However, 5-year mortality rates remain high and the prevalence of the disease is rising likely due to aging of the population and advances in diagnosis and treatment of other acute and chronic cardiovascular diseases. Over the past three decades the therapeutic armamentarium of heart failure has improved substantially with development of medications targeting neuro-hormonal activation and devices preventing sudden cardiac death and improving cardiac synchrony. Recently, inhibition of angiotensin receptors and neprilysin as well as sinoatrial pacemaker modulating f-current, have been found safe and effective strategies that improve HF hospitalization rates and/or mortality. Antidiabetic agents inhibiting sodium-glucose co-transporters 2, result in natriuresis and osmotic diuresis and may further improve HF related outcomes. Furthermore, emerging therapies such as cardiac myosin activators, soluble guanylate cyclase stimulators and non-steroidal mineralocorticoid receptor antagonists are undergoing investigation in phase II and III studies of HF patients. Finally, rapid evolution of in the management of advanced HF has occurred with the application of second and third generation continuous flow left ventricular assist devices in clinical practice. Ongoing clinical studies will validate the safety and efficacy of emerging therapeutic strategies in HF population underrepresented in previous clinical trials.
No takes yet. Share an insight, caveat, or question.
Briasoulis et al. (2019) conducted a review in Heart Failure. New Pharmaceutical and Device Options was evaluated. Recent advances in heart failure management, including angiotensin receptor-neprilysin inhibitors, SGLT2 inhibitors, and left ventricular assist devices, offer new therapeutic options.
Synapse has enriched 10 related papers. Consider them for comparative context: